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doi:10.1016/j.jmii.2011.09.003There are no previous study about ocular toxoplasmosis and serum levels of dehydroepian-
drosterone sulphated hormone (DHEAS). We use the chemoluminiscence automatized Immu-
lite assay to determine the levels of DHEAS. Four groups were studied: (1) Individuals with
chronic asymptomatic infection with a positive test for IgG anti-Toxoplasma and without
ocular lesions (nZ 16); (2) Chronic asymptomatic patients with retinal scars of retinochoroi-
ditis by Toxoplasma (nZ 19); (3) Acute symptomatic patients with active retinochoroiditis by
Toxoplasma (n Z 26); (4) Individuals with negative assays for IgG anti-Toxoplasma (n Z 21).
Comparison of DHEAS levels between groups were adjusted by age and sex and non-
parametric Kruskall Wallis statistical tests were applied. No significant differences in serum
levels of DHEAS were found between groups when age and sex were controlled. DHEAS levels
were not significantly different in active ocular toxoplasmosis related to non active or non
infected persons.
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Ocular toxoplasmosis is the most common infectious
cause of retinochoroidal inflammation in immunocompe-
tent individuals and is one of the most important causesished by Elsevier Taiwan LLC. All rights reserved.
66 A. de-la-Torre et al.of visual damage in some countries.1 Thus, in Colombia,
it is estimated that 6% of the population has reti-
nochoroidal scars after a non congenital infection and
20% of these persons have reduced visual capacity.2
Recurrent retinochoroiditis is a typical characteristic of
ocular toxoplasmosis and the factors related to this
remain to be discovered.3 In a field study in Brazil,
a relation between puberty, gender and apparition of
new lesions in ocular toxoplasmosis was described.4 A
hormonal factor triggering recurrences has been evo-
cated but the precise hormones linked to these events
have not been studied.
In recent years there has been strong speculation that
puberty-related hormones, dehydroepiandrosterone (DHEA)
in particular, might play some role in inducing resistance
during Schistosoma, HIV and malaria infections.5e7 DHEA is
one of the steroid hormones produced by the adrenal cortex
and is found mostly in its sulfate form, DHEA sulfate
(DHEAS); it is converted to DHEA by DHEA sulfatase.8 The
secretion of DHEAS is high just before birth and again at
puberty, and the maximum concentration is reached at
around 20 to 30 years of age, followed by a progressive
decline with age. DHEAS is implicated in age-related
changes in the immune system and has been associated
with disease susceptibility.9 To our knowledge, no report
has been made of the DHEAS levels during human
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Figure 1. Age-related DHEAS levels in: (A) women with active o
ocular lesions with positive or negative Toxoplasma serology; (C) m
(D) men without ocular lesions with positive or negative Toxopla
Values are expressed in mg/dL of DHEAS.Materials and methods
Patients
Four groups of patients were studied: (1) acute symptomatic
patients with active retinochoroiditis by Toxoplasma
(nZ 26); (2) chronic asymptomatic patientswith retinal scars
of retinochoroiditis by Toxoplasma (n Z 19); (3) individuals
with chronic asymptomatic infection with a positive test for
anti-Toxoplasma IgG and without ocular lesions (nZ 16); and
(4) individuals with negative assays for anti-Toxoplasma IgG
(n Z 21). Diagnosis criteria for active retinochoroiditis and
chronic inactive retinal scar were as described previously.2
Patients without ocular lesions but with positive Toxo-
plasma serology and those without ocular lesions but nega-
tive for Toxoplasma serology were volunteers identified
during fundoscopy ocular screening at the University of
Quindio.2 Anti-Toxoplasma IgG antibodies were measured by
the Enzyme-Linked Immunosorbent Assay (ELISA) Test
(Diagnostic Systems Laboratories Inc, Webster, Texas, USA).
Determination of DHEAS
DHEAS was measured with an immunoluminometric assay
(DPC, Los Angeles, USA) with an intra-assay coefficient of
variation of 9%. Levels were expressed in mg/dL.Age related DHEAS level: Active vs. inactive scar in women
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Table 1 Distribution of median levels of DHEAS in women by group
Women n Mean age (y) 
standard deviation
Median DHEAS
levels (mg/dL)
Range p*
Active toxoplasmic retinochoroidal lesion 17 26  11 58 15e700 e
Inactive toxoplasmic chorioretinal lesion 8 29  13 95 41e246 0.12
Toxoplasma positive control without
retinal lesion e age 20 to 30 y
5 28  6 113 20e136 e
Toxoplasma negative control without
retinal lesion e age 20 to 30 y
8 22  4 122 33e295 0.30
* Kruskall Wallis test for nonparametric data, significant differences if p < 0.05.
Table 2 Distribution of median levels of DHEAS in men by group
Men n Age mean 
Standard deviation
Median DHEAS
levels mg/dl
Range p*
Active toxoplasmic retinochoroidal lesion 9 27  9 206 49e520 e
Inactive toxoplasmic chorioretinal lesion 11 24  7 199 75e369 0.79
Toxoplasma positive control without retinal lesion 7 28  5 177 39e249 e
Toxoplasma negative control without retinal lesion 9 20  2 161 82e268 0.87
* Kruskall Wallis test for nonparametric data, significant differences if p < 0.05.
Serum DHEAS in ocular toxoplasmosisStatistical analysis
Comparisons of DHEAS levels between groups were strati-
fied by age and sex and non-parametric Kruskall Wallis
statistical tests were applied. The Epi-info computer pro-
gramme (CDC, Atlanta, Georgia, USA) was used for analysis
of data.
Results and discussion
Levels of DHEAS were significantly different between
women (median Z 73 mg/dL, range 15e70 mg/dL) and men
(184 mg/dL, range 39e520 mg/dL). Subsequent analyses
were made separately for men and women. We compared
patients with ocular lesions with active inflammatory reti-
nochoroidal lesion by Toxoplasma versus patients with an
inactive toxoplasmic retinochoroidal scar and patients
without ocular lesion but positive Toxoplasma serology
versus patients without ocular lesion and negative Toxo-
plasma serology. Age means were not different between
the groups with the exception of women without ocular
lesions. Therefore, for these two groups of women (positive
versus negative Toxoplasma serology), comparisons of
DHEAS levels were made only between women with an age
range of 20 years to 30 years. As shown in Fig. 1, DHEAS
levels were higher between the ages of 20 years and 40
years. No significant differences of DHEAS levels were found
by comparing the groups of active versus inactive chorior-
etinal lesions or in people without ocular lesions between
positive or negative Toxoplasma serology (Tables 1 and 2).
There were no significant differences between the
active or inactive lesions in ocular toxoplasmosis or in
infected versus non infected patients with Toxoplasma.
DHEAS levels were significantly affected by age and sex;
when we controlled the groups for comparison, no differ-
ences were found with regards to the infection status.
Interestingly, the two higher values for DHEAS in all groupswere found in two patients (one male, one female) with
active chorioretinal Toxoplasma lesions.
Although the intrinsic correlation of DHEAS and the
immune system merits further exploration10 regarding the
role of this hormone in human toxoplasmosis, our present
results indicate that the levels of DHEAS are not useful to
indicate activity and that they are not altered significantly
in ocular toxoplasmosis.Acknowledgments
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